Tamox – Tamoxifen Citrate 20mg
Tamox is presented in the ORYVION catalog as a tablet formulation containing tamoxifen citrate, with a declared strength of 20mg per tablet, supplied in containers of 50 tablets. Tamoxifen is an orally active, nonsteroidal selective estrogen receptor modulator (SERM).
Its pharmacological profile involves binding to estrogen receptors, blocking estrogen’s effects in some tissues while producing estrogen-like effects in others. In breast tissue, this action can inhibit the growth of estrogen-sensitive cancer cells. Its established medical applications include the treatment of certain breast cancers and breast cancer risk reduction in selected patients.
Product Specifications:
Commercial name: Tamox
Listed compound: Tamoxifen Citrate
Declared strength: 20mg per tablet
Format: Tablets
Package contents: 50 tablets
Important Note:
Tamoxifen can increase the risk of blood clots, including deep-vein thrombosis and pulmonary embolism. Serious risks also include stroke and uterine malignancies in patients with a uterus. Other adverse effects include hot flashes, menstrual disturbances, and cataracts.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.